•  
  •  
  •  
  •  

2025-12-26 18:07:37

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Nifty Extends Losses for Second Day, IT and Auto Stocks Lead the Fall
  • TCI adds 1.5 Lakh Sq. Ft. Cold Chain Capacity at Taj Nagar, Gurugram
  • G E Shipping contracts to sell its 2002 built Very Large Gas Carrier 'Jag Vishnu'
  • Ceigall Bathinda Dabwali Highways Pvt Ltd receives Provisional Certificate
  • Avasara Finance Ltd fixes Jan 1, 2026 as record date for 2:1 rights issue

Keywords Selected:  EU

Research

  • Tata Motors CV Listing: A Strong Value Unlock Story
  • CRISIL: Pharmaceutical sector set for 8-10% revenue growth this fiscal
  • Axis Securities' Monthly Auto Volume Update - July 2024
  • Kotak Institutional Equities - Pharmaceuticals: IPM pulse - gaining momentum
  • CRISIL Ratings: Slowing US, EU to chip 6-8% away from handicraft sales this fiscal
  • 10,000+ women entrepreneurs have dispensed over ₹900 crores of financial services in the last financial year: PayNearby Study
  • Company Update - P&G Health - ICICI Direct
  • ICRA's sample set of Indian pharmaceutical companies to grow by 6-7% in FY2023: ICRA
  • Quant Pick - Cadila Healthcare - ICICI Direct
  • Q2FY22 Result Update - Syngene International - ICICI Direct
  • Syngene International Ltd - Lack of near term triggers - YES Securities
  • Syngene International Ltd - Lower gross margin lead to EBIDTA miss - YES Securities

Market Commentary

  • Mr. Asheesh Chanda, Founder & CEO, Kristal.AI on depreciation of Euro against USD
  • Finance Minister announces reduction of Central Excise Duty on Petrol, Diesel
  • India must regulate cryptocurrencies in consumer interest and to promote innovation: Esya Centre, ORF report

IPO News

  • Accretion Pharmaceuticals' IPO Opens for subscription today, Price Band set at ₹96-101 per Share
  • Accretion Pharmaceuticals Ltd IPO to open for subscription on May 14, 2025
  • Leading Decorative Wall Panel & Premium Laminates Brand Euro Pratik files DRHP for Rs 730 crore IPO
  • Senores Pharmaceuticals IPO subscribed 13.93 times on Day 2
  • Senores Pharmaceuticals IPO fully subscribed on Day 1
  • Senores Pharmaceuticals gets Sebi nod for IPO

Stock Report

  • Strides Pharma Inc's Chestnut Ridge facility gets 4 observations from USFDA
  • Fermenta ranked among India's Best Workplaces™ in Pharmaceuticals, Healthcare & Biotech by Great Place to Work®
  • Zydus partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®
  • Ajanta signs in-licensing agreement with Biocon for marketing Semaglutide in 26 countries
  • Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial
  • CORONA Remedies Ltd commissions additional capacity
  • Shukra Pharmaceuticals Ltd receives authorization from Univlabs Technologies Pvt. Ltd.
  • Emcure expands weight management therapy access with Launch of Poviztra®
  • Granules Pharmaceuticals Inc. receives FDA tentative approval for Generic Amphetamine Extended-Release Orally Disintegrating Tablets
  • Archean Chemical Industries Ltd enters into loan agreement with Neun Infra Pvt Ltd
  • Sai Life Sciences Releases Sustainability Report 2024-25
  • Pfizer & Cipla announce Exclusive Marketing and Distribution Partnership for Select Brands in India
  • Zydus Lifesciences Limited signs an exclusive agreement with Myriad Genetics of US to launch cancer-risk assessment diagnostic tests in India
  • Aksharchem India Ltd commissions ground mounted solar power plant
  • Lupin signs exclusive licensing agreement with Neopharmed for Gastroenterology Brand Plasil® in the Philippines and Brazil
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Travoprost Ophthalmic Solution USP, 0.004%
  • APL Healthcare Ltd's Unit-4 gets 5 observations from USFDA
  • Nucleus for India - Synapse 2025 Unveils India's AI-Defined Banking Blueprint and Announces Global Release of FinnOne Neo® GA 8.5
  • US FDA determines Sun Pharma's Baska facility inspection classification as OAI
  • ACME Solar secures INR 4,725 crore financing and expands banking base
  • AstraZeneca Pharma India Ltd receives permission from CDSCO for Datopotamab Deruxtecan powder
  • CPCL enters into MoA with Manali Petrochemicals Ltd
  • Sathgen Therapeutics Division expands to the U.S. with Launch of Princeton Based Subsidiary
  • Lupin receives Positive CHMP Opinion for Biosimilar Ranibizumab

Industry News

  • Healthcare diagnostics startup Neuranics Raises $700K US Funding in Seed Round Led by Inflection Point Ventures
  • Wundrsight raises USD 400K in a Seed Round led by Inflection Point Ventures
  • Neo Raises INR 400 Crore in Latest Funding Round Led by MUFG and Euclidean Capital
  • NSE's consolidated Q1 FY25 operating revenue up by 51% YoY at Rs.4,510 crores
  • Agoda: More Europeans Searching for Travel to Asia This Summer
  • HCL Group and UpLink Open Applications for its Third Global Aquapreneur Innovation Challenge
  • Honeywell Launches World's First 100% Hydrogen-Capable Gas Meter
  • MakeMyTrip launches a gamut of customizable holiday packages for Europe
  • FLAME University launches an interdisciplinary Bachelor of Design program
  • The UNLEASH Global Innovation Lab brings together youth to create disruptive solutions that fast-track SDG progress
  • NYSE Listed Amneal Pharmaceuticals begins Commercial Operations in India
  • MakeMyTrip joins hands with Climes to encourage travellers to neutralize their flight emissions

Latest Post

  • Nifty Extends Losses for Second Day, IT and Auto Stocks Lead the Fall
  • TCI adds 1.5 Lakh Sq. Ft. Cold Chain Capacity at Taj Nagar, Gurugram
  • G E Shipping contracts to sell its 2002 built Very Large Gas Carrier 'Jag Vishnu'
  • Ceigall Bathinda Dabwali Highways Pvt Ltd receives Provisional Certificate
  • Avasara Finance Ltd fixes Jan 1, 2026 as record date for 2:1 rights issue


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024